Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of CYD Dengue Vaccine Schedules
NCT02628444Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2016
- Primary completion
- Apr 2020
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever (9 arms), sponsored by Sanofi. Primary endpoint: Geometric Mean Titers Against Each Dengue Virus Serotype. Started May 2016; status: completed.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02628444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02628444.